RGNX (REGENXBIO Corp) Return on Gross Profit

Official company branding of Regenxbio (RGNX)

Proprietary viral vector developments ensure the operational resilience of REGENXBIO Inc. (RGNX), as evidenced by the gross margin history in the GURU.Markets terminal, where 77.80 defines the current value of the metric. Revenues are based on Zolgensma licenses and royalties, while a strong biotech reputation guarantees institutional trust. The company's strategy relies on the commercialization of innovative treatments for the brain and eyes.

RGNX regenxbio.com Gross Profitability (07/04/2022 - 11/20/2026)

Analytical breakdowns and data insights for company REGENXBIO (RGNX)

- stock quotes and analyst forecast:
Summary company analysis:REGENXBIO
Original product of regenxbio.com

For REGENXBIO Inc. (RGNX), the base gross margin reflects the monetization efficiency of the NAV platform, demonstrating the profit share after deducting direct production costs. This indicator measures operating profitability, where high sensitivity to gene therapy manufacturing costs is balanced by a steady stream of licensing royalties, confirming the resilience of the company's patent advantage in its fundamental valuation.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|solidbio.com (SLDB) - Return on Sales by Gross Profit|Gross Profitability Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Gross Return on Sales|Benitec Biopharma - Return on Gross Profit|DSGN: Gross Return on Sales|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability